ID   MBD1_HUMAN              Reviewed;         605 AA.
AC   Q9UIS9; A4UTZ0; B4DXJ5; E9PEC5; K7ELI2; K7EQZ4; K7ESN0; O15248; O95241;
AC   Q7Z7B5; Q8N4W4; Q9UNZ6; Q9UNZ7; Q9UNZ8; Q9UNZ9;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2004, sequence version 2.
DT   07-APR-2021, entry version 197.
DE   RecName: Full=Methyl-CpG-binding domain protein 1 {ECO:0000305};
DE   AltName: Full=CXXC-type zinc finger protein 3;
DE   AltName: Full=Methyl-CpG-binding protein MBD1;
DE   AltName: Full=Protein containing methyl-CpG-binding domain 1;
GN   Name=MBD1 {ECO:0000312|HGNC:HGNC:6916}; Synonyms=CXXC3, PCM1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), FUNCTION, INTERACTION WITH THE
RP   MECP1 COMPLEX, AND TISSUE SPECIFICITY.
RX   PubMed=9207790; DOI=10.1038/ng0797-256;
RA   Cross S.H., Meehan R.R., Nan X., Bird A.;
RT   "A component of the transcriptional repressor MeCP1 shares a motif with DNA
RT   methyltransferase and HRX proteins.";
RL   Nat. Genet. 16:256-259(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ALA-401.
RX   PubMed=10441743; DOI=10.1007/s003359901112;
RA   Hendrich B., Abbott C., McQueen H., Chambers D., Cross S.H., Bird A.;
RT   "Genomic structure and chromosomal mapping of the murine and human mbd1,
RT   mbd2, mbd3, and mbd4 genes.";
RL   Mamm. Genome 10:906-912(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 4 AND 7), FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Fibroblast;
RX   PubMed=10454587; DOI=10.1128/mcb.19.9.6415;
RA   Fujita N., Takebayashi S., Okumura K., Kudo S., Chiba T., Saya H.,
RA   Nakao M.;
RT   "Methylation-mediated transcriptional silencing in euchromatin by methyl-
RT   CpG binding protein MBD1 isoforms.";
RL   Mol. Cell. Biol. 19:6415-6426(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 6), INDUCTION BY INTERFERON, AND INTERACTION
RP   WITH OASL.
RC   TISSUE=Leukocyte;
RX   PubMed=14728690; DOI=10.1046/j.1432-1033.2003.03966.x;
RA   Andersen J.B., Strandbygaard D.J., Hartmann R., Justesen J.;
RT   "Interaction between the 2'-5' oligoadenylate synthetase-like protein p59
RT   OASL and the transcriptional repressor methyl CpG-binding protein 1.";
RL   Eur. J. Biochem. 271:628-636(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 8).
RC   TISSUE=Cervix carcinoma;
RA   Laget S.M., Xu S.-Y.;
RT   "New splice variant of the methyl-CpG binding protein 1 (MBD1).";
RL   Submitted (MAR-2007) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 9).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16177791; DOI=10.1038/nature03983;
RA   Nusbaum C., Zody M.C., Borowsky M.L., Kamal M., Kodira C.D., Taylor T.D.,
RA   Whittaker C.A., Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Abouelleil A., Allen N.R., Anderson S., Bloom T., Bugalter B., Butler J.,
RA   Cook A., DeCaprio D., Engels R., Garber M., Gnirke A., Hafez N., Hall J.L.,
RA   Norman C.H., Itoh T., Jaffe D.B., Kuroki Y., Lehoczky J., Lui A.,
RA   Macdonald P., Mauceli E., Mikkelsen T.S., Naylor J.W., Nicol R., Nguyen C.,
RA   Noguchi H., O'Leary S.B., Piqani B., Smith C.L., Talamas J.A., Topham K.,
RA   Totoki Y., Toyoda A., Wain H.M., Young S.K., Zeng Q., Zimmer A.R.,
RA   Fujiyama A., Hattori M., Birren B.W., Sakaki Y., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 18.";
RL   Nature 437:551-555(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 7).
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 169-220, AND FUNCTION.
RX   PubMed=9774669; DOI=10.1128/mcb.18.11.6538;
RA   Hendrich B., Bird A.;
RT   "Identification and characterization of a family of mammalian methyl-CpG
RT   binding proteins.";
RL   Mol. Cell. Biol. 18:6538-6547(1998).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=10648624; DOI=10.1128/mcb.20.4.1394-1406.2000;
RA   Ng H.-H., Jeppesen P., Bird A.;
RT   "Active repression of methylated genes by the chromosomal protein MBD1.";
RL   Mol. Cell. Biol. 20:1394-1406(2000).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH THE SUV39H1-CBX5
RP   COMPLEX.
RX   PubMed=12711603; DOI=10.1074/jbc.m302283200;
RA   Fujita N., Watanabe S., Ichimura T., Tsuruzoe S., Shinkai Y., Tachibana M.,
RA   Chiba T., Nakao M.;
RT   "Methyl-CpG binding domain 1 (MBD1) interacts with the Suv39h1-HP1
RT   heterochromatic complex for DNA methylation-based transcriptional
RT   repression.";
RL   J. Biol. Chem. 278:24132-24138(2003).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH ATF7IP.
RX   PubMed=12665582; DOI=10.1128/mcb.23.8.2834-2843.2003;
RA   Fujita N., Watanabe S., Ichimura T., Ohkuma Y., Chiba T., Saya H.,
RA   Nakao M.;
RT   "MCAF mediates MBD1-dependent transcriptional repression.";
RL   Mol. Cell. Biol. 23:2834-2843(2003).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH CHAF1A.
RX   PubMed=12697822; DOI=10.1128/mcb.23.9.3226-3236.2003;
RA   Reese B.E., Bachman K.E., Baylin S.B., Rountree M.R.;
RT   "The methyl-CpG binding protein MBD1 interacts with the p150 subunit of
RT   chromatin assembly factor 1.";
RL   Mol. Cell. Biol. 23:3226-3236(2003).
RN   [14]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=14610093; DOI=10.1074/jbc.m309393200;
RA   Ghoshal K., Majumder S., Datta J., Motiwala T., Bai S., Sharma S.M.,
RA   Frankel W., Jacob S.T.;
RT   "Role of human ribosomal RNA (rRNA) promoter methylation and of methyl-CpG-
RT   binding protein MBD2 in the suppression of rRNA gene expression.";
RL   J. Biol. Chem. 279:6783-6793(2004).
RN   [15]
RP   RETRACTED PAPER.
RX   PubMed=15327775; DOI=10.1016/j.molcel.2004.06.043;
RA   Sarraf S.A., Stancheva I.;
RT   "Methyl-CpG binding protein MBD1 couples histone H3 methylation at lysine 9
RT   by SETDB1 to DNA replication and chromatin assembly.";
RL   Mol. Cell 15:595-605(2004).
RN   [16]
RP   RETRACTION NOTICE OF PUBMED:15327775.
RX   PubMed=30849389; DOI=10.1016/j.molcel.2019.02.023;
RA   Sarraf S.A., Stancheva I.;
RT   "Retraction Notice to: Methyl-CpG Binding Protein MBD1 Couples Histone H3
RT   Methylation at Lysine 9 by SETDB1 to DNA Replication and Chromatin
RT   Assembly.";
RL   Mol. Cell 73:1084-1084(2019).
RN   [17]
RP   INTERACTION WITH ATF7IP AND ATF7IP2, AND MUTAGENESIS OF ILE-576.
RX   PubMed=15691849; DOI=10.1074/jbc.m413654200;
RA   Ichimura T., Watanabe S., Sakamoto Y., Aoto T., Fujita N., Nakao M.;
RT   "Transcriptional repression and heterochromatin formation by MBD1 and
RT   MCAF/AM family proteins.";
RL   J. Biol. Chem. 280:13928-13935(2005).
RN   [18]
RP   RETRACTED PAPER.
RX   PubMed=17066076; DOI=10.1038/sj.emboj.7601404;
RA   Lyst M.J., Nan X., Stancheva I.;
RT   "Regulation of MBD1-mediated transcriptional repression by SUMO and PIAS
RT   proteins.";
RL   EMBO J. 25:5317-5328(2006).
RN   [19]
RP   RETRACTION NOTICE OF PUBMED:17066076.
RX   PubMed=31612521; DOI=10.15252/embj.2019103220;
RA   Lyst M.J., Nan X., Stancheva I.;
RT   "Retraction: Regulation of MBD1-mediated transcriptional repression by SUMO
RT   and PIAS proteins.";
RL   EMBO J. 38:e103220-e103220(2019).
RN   [20]
RP   SUMOYLATION, AND INTERACTION WITH ATF7IP.
RX   PubMed=16757475; DOI=10.1074/jbc.m602280200;
RA   Uchimura Y., Ichimura T., Uwada J., Tachibana T., Sugahara S., Nakao M.,
RA   Saitoh H.;
RT   "Involvement of SUMO modification in MBD1- and MCAF1-mediated
RT   heterochromatin formation.";
RL   J. Biol. Chem. 281:23180-23190(2006).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-399, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [22]
RP   INTERACTION WITH BAHD1.
RX   PubMed=19666599; DOI=10.1073/pnas.0901259106;
RA   Bierne H., Tham T.N., Batsche E., Dumay A., Leguillou M.,
RA   Kerneis-Golsteyn S., Regnault B., Seeler J.S., Muchardt C., Feunteun J.,
RA   Cossart P.;
RT   "Human BAHD1 promotes heterochromatic gene silencing.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:13826-13831(2009).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-399, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-391, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-297, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-538, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [28]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-538, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [29]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-277 AND LYS-422, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [30]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-117; LYS-277; LYS-422; LYS-440;
RP   LYS-499; LYS-538 AND LYS-558, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [31]
RP   STRUCTURE BY NMR OF 1-75 IN COMPLEX WITH METHYLATED DNA, AND MUTAGENESIS OF
RP   ARG-22; ARG-30; ASP-32; TYR-34; ARG-44; SER-45; TYR-52 AND PHE-64.
RX   PubMed=10581239; DOI=10.1093/emboj/18.23.6653;
RA   Ohki I., Shimotake N., Fujita N., Nakao M., Shirakawa M.;
RT   "Solution structure of the methyl-CpG-binding domain of the methylation-
RT   dependent transcriptional repressor MBD1.";
RL   EMBO J. 18:6653-6661(1999).
RN   [32] {ECO:0007744|PDB:1IG4}
RP   STRUCTURE BY NMR OF 1-75 IN COMPLEX WITH METHYLATED DNA, DOMAIN MBD, AND
RP   MUTAGENESIS OF ARG-22; ARG-30; ASP-32; TYR-34; ARG-44; SER-45; LYS-46;
RP   TYR-52 AND LYS-65.
RX   PubMed=11371345; DOI=10.1016/s0092-8674(01)00324-5;
RA   Ohki I., Shimotake N., Fujita N., Jee J., Ikegami T., Nakao M.,
RA   Shirakawa M.;
RT   "Solution structure of the methyl-CpG binding domain of human MBD1 in
RT   complex with methylated DNA.";
RL   Cell 105:487-497(2001).
RN   [33]
RP   STRUCTURE BY NMR OF 1-75 IN COMPLEX WITH METHYLATED DNA, FUNCTION,
RP   SUBCELLULAR LOCATION, INTERACTION WITH MPG, AND DOMAIN TRD.
RX   PubMed=14555760; DOI=10.1073/pnas.2131819100;
RA   Watanabe S., Ichimura T., Fujita N., Tsuruzoe S., Ohki I., Shirakawa M.,
RA   Kawasuji M., Nakao M.;
RT   "Methylated DNA-binding domain 1 and methylpurine-DNA glycosylase link
RT   transcriptional repression and DNA repair in chromatin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:12859-12864(2003).
RN   [34] {ECO:0007744|PDB:4D4W}
RP   STRUCTURE BY NMR OF 167-222, AND DOMAIN CXXC-TYPE 1 ZINC-FINGER.
RX   PubMed=26354109; DOI=10.1007/s10858-015-9986-8;
RA   Thomson R., Smith B.O.;
RT   "Solution structure of human MBD1 CXXC1.";
RL   J. Biomol. NMR 63:309-314(2015).
RN   [35] {ECO:0007744|PDB:5W9Q}
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 330-388 IN COMPLEX WITH CPG DNA,
RP   DOMAIN CXXC-TYPE 3 ZINC-FINGER, AND ZINC-BINDING.
RX   PubMed=29276034; DOI=10.1016/j.str.2017.11.022;
RA   Xu C., Liu K., Lei M., Yang A., Li Y., Hughes T.R., Min J.;
RT   "DNA Sequence Recognition of Human CXXC Domains and Their Structural
RT   Determinants.";
RL   Structure 26:85-95.e3(2018).
RN   [36] {ECO:0007744|PDB:6D1T}
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 1-77 IN COMPLEX WITH METHYLATED
RP   DNA, AND DOMAIN MBD.
RG   Structural genomics consortium (SGC);
RT   "Complex of MBD1-MBD and methylated DNA.";
RL   Submitted (APR-2018) to the PDB data bank.
CC   -!- FUNCTION: Transcriptional repressor that binds CpG islands in promoters
CC       where the DNA is methylated at position 5 of cytosine within CpG
CC       dinucleotides. Binding is abolished by the presence of 7-mG that is
CC       produced by DNA damage by methylmethanesulfonate (MMS). Acts as
CC       transcriptional repressor and plays a role in gene silencing by
CC       recruiting ATF7IP, which in turn recruits factors such as the histone
CC       methyltransferase SETDB1. Probably forms a complex with SETDB1 and
CC       ATF7IP that represses transcription and couples DNA methylation and
CC       histone 'Lys-9' trimethylation. Isoform 1 and isoform 2 can also
CC       repress transcription from unmethylated promoters.
CC       {ECO:0000269|PubMed:10454587, ECO:0000269|PubMed:10648624,
CC       ECO:0000269|PubMed:12665582, ECO:0000269|PubMed:12697822,
CC       ECO:0000269|PubMed:12711603, ECO:0000269|PubMed:14555760,
CC       ECO:0000269|PubMed:14610093, ECO:0000269|PubMed:9207790,
CC       ECO:0000269|PubMed:9774669}.
CC   -!- SUBUNIT: Interacts with OASL, ATF7IP, ATF7IP2 and BAHD1
CC       (PubMed:12665582, PubMed:14728690, PubMed:15691849, PubMed:16757475,
CC       PubMed:19666599). Binds CHAF1A and the SUV39H1-CBX5 complex via the MBD
CC       domain (PubMed:12697822, PubMed:12711603). Binds MGP via the TRD domain
CC       (PubMed:14555760). May be part of the MeCP1 complex (PubMed:9207790).
CC       {ECO:0000269|PubMed:12665582, ECO:0000269|PubMed:12697822,
CC       ECO:0000269|PubMed:12711603, ECO:0000269|PubMed:14555760,
CC       ECO:0000269|PubMed:14728690, ECO:0000269|PubMed:15691849,
CC       ECO:0000269|PubMed:16757475, ECO:0000269|PubMed:19666599,
CC       ECO:0000269|PubMed:9207790}.
CC   -!- INTERACTION:
CC       Q9UIS9; P45973: CBX5; NbExp=6; IntAct=EBI-867196, EBI-78219;
CC       Q9UIS9; Q13111: CHAF1A; NbExp=3; IntAct=EBI-867196, EBI-1020839;
CC       Q9UIS9; Q13547: HDAC1; NbExp=2; IntAct=EBI-867196, EBI-301834;
CC       Q9UIS9; Q92769: HDAC2; NbExp=2; IntAct=EBI-867196, EBI-301821;
CC       Q9UIS9; O15379: HDAC3; NbExp=3; IntAct=EBI-867196, EBI-607682;
CC       Q9UIS9; P42858: HTT; NbExp=2; IntAct=EBI-867196, EBI-466029;
CC       Q9UIS9; Q99435: NELL2; NbExp=2; IntAct=EBI-867196, EBI-946274;
CC       Q9UIS9; O75925: PIAS1; NbExp=3; IntAct=EBI-867196, EBI-629434;
CC       Q9UIS9; Q9Y6X2: PIAS3; NbExp=3; IntAct=EBI-867196, EBI-2803703;
CC       Q9UIS9; Q15156: PML-RAR; NbExp=4; IntAct=EBI-867196, EBI-867256;
CC       Q9UIS9; Q15047: SETDB1; NbExp=3; IntAct=EBI-867196, EBI-79691;
CC       Q9UIS9; P63165: SUMO1; NbExp=3; IntAct=EBI-867196, EBI-80140;
CC       Q9UIS9; O43463: SUV39H1; NbExp=5; IntAct=EBI-867196, EBI-349968;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12711603,
CC       ECO:0000269|PubMed:14610093}. Nucleus matrix
CC       {ECO:0000269|PubMed:10454587, ECO:0000269|PubMed:10648624}. Nucleus
CC       speckle {ECO:0000269|PubMed:10454587, ECO:0000269|PubMed:10648624}.
CC       Chromosome {ECO:0000269|PubMed:10454587, ECO:0000269|PubMed:10648624,
CC       ECO:0000269|PubMed:12711603, ECO:0000269|PubMed:14555760}.
CC       Note=Nuclear, in a punctate pattern (PubMed:12711603). Associated with
CC       euchromatic regions of the chromosomes, with pericentromeric regions on
CC       chromosome 1 and with telomeric regions from several chromosomes
CC       (PubMed:10648624, PubMed:10454587). {ECO:0000269|PubMed:10454587,
CC       ECO:0000269|PubMed:10648624, ECO:0000269|PubMed:12711603}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=11;
CC       Name=1; Synonyms=MBD1v1;
CC         IsoId=Q9UIS9-1; Sequence=Displayed;
CC       Name=2; Synonyms=MBD1v2;
CC         IsoId=Q9UIS9-2; Sequence=VSP_011065, VSP_011068, VSP_011070;
CC       Name=4; Synonyms=MBD1v3;
CC         IsoId=Q9UIS9-4; Sequence=VSP_011066, VSP_011068;
CC       Name=5; Synonyms=PCM1;
CC         IsoId=Q9UIS9-5; Sequence=VSP_011064;
CC       Name=6; Synonyms=MBD1v6;
CC         IsoId=Q9UIS9-6; Sequence=VSP_011068, VSP_011069, VSP_011071;
CC       Name=7;
CC         IsoId=Q9UIS9-7; Sequence=VSP_011066;
CC       Name=8;
CC         IsoId=Q9UIS9-8; Sequence=VSP_011065, VSP_011068;
CC       Name=9;
CC         IsoId=Q9UIS9-9; Sequence=VSP_042812;
CC       Name=10;
CC         IsoId=Q9UIS9-10; Sequence=VSP_011064, VSP_054737, VSP_054738;
CC       Name=11;
CC         IsoId=Q9UIS9-11; Sequence=VSP_054736, VSP_011068, VSP_054739;
CC       Name=12;
CC         IsoId=Q9UIS9-12; Sequence=VSP_011070;
CC   -!- TISSUE SPECIFICITY: Widely expressed. {ECO:0000269|PubMed:9207790}.
CC   -!- INDUCTION: Up-regulated by interferon. {ECO:0000269|PubMed:14728690}.
CC   -!- DOMAIN: The methyl-CpG-binding domain (MBD) functions both in binding
CC       to methylated DNA and in protein interactions.
CC       {ECO:0000269|PubMed:10581239}.
CC   -!- DOMAIN: The third CXXC-type zinc finger mediates binding to DNA
CC       containing unmethylated CpG dinucleotides.
CC       {ECO:0000269|PubMed:29276034}.
CC   -!- DOMAIN: The transcriptional repression domain (TRD) is involved in
CC       transcription repression and in protein interactions.
CC       {ECO:0000269|PubMed:14555760}.
CC   -!- PTM: Sumoylated, sumoylation may increase interaction with ATF7IP.
CC       {ECO:0000269|PubMed:16757475}.
CC   -!- CAUTION: Was reported to recruit SETDB1 during DNA replication, to form
CC       a S phase-specific complex that would facilitate methylation of H3
CC       'Lys-9' during replication-coupled chromatin assembly and vould be at
CC       least composed of the CAF-1 subunit CHAF1A, MBD1 and SETDB1
CC       (PubMed:15327775). The interaction with SETDB1 was also reported to be
CC       inhibited by sumoylation at Lys-499 and Lys-538 (PubMed:17066076).
CC       However, these papers have been retracted because some data, results
CC       and conclusions are not reliable (PubMed:30849389, PubMed:31612521).
CC       {ECO:0000269|PubMed:15327775, ECO:0000269|PubMed:17066076,
CC       ECO:0000269|PubMed:30849389, ECO:0000269|PubMed:31612521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y10746; CAA71735.1; -; mRNA.
DR   EMBL; AF120981; AAD50371.1; -; Genomic_DNA.
DR   EMBL; AF120980; AAD50371.1; JOINED; Genomic_DNA.
DR   EMBL; AF078830; AAD51442.1; -; mRNA.
DR   EMBL; AF078831; AAD51443.1; -; mRNA.
DR   EMBL; AF078832; AAD51444.1; -; mRNA.
DR   EMBL; AF078833; AAD51445.1; -; mRNA.
DR   EMBL; EF488685; ABP02056.1; -; mRNA.
DR   EMBL; AK302004; BAG63407.1; -; mRNA.
DR   EMBL; AC090246; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC033242; AAH33242.1; -; mRNA.
DR   EMBL; AJ564845; CAD92308.1; -; mRNA.
DR   EMBL; AF072241; AAC68870.1; -; mRNA.
DR   CCDS; CCDS11941.1; -. [Q9UIS9-4]
DR   CCDS; CCDS11942.1; -. [Q9UIS9-7]
DR   CCDS; CCDS11943.1; -. [Q9UIS9-1]
DR   CCDS; CCDS11944.1; -. [Q9UIS9-5]
DR   CCDS; CCDS32832.1; -. [Q9UIS9-2]
DR   CCDS; CCDS56071.1; -. [Q9UIS9-8]
DR   CCDS; CCDS56072.1; -. [Q9UIS9-6]
DR   CCDS; CCDS56073.1; -. [Q9UIS9-9]
DR   CCDS; CCDS59318.1; -. [Q9UIS9-10]
DR   CCDS; CCDS59319.1; -. [Q9UIS9-11]
DR   CCDS; CCDS59320.1; -. [Q9UIS9-12]
DR   RefSeq; NP_001191065.1; NM_001204136.1. [Q9UIS9-12]
DR   RefSeq; NP_001191066.1; NM_001204137.1. [Q9UIS9-9]
DR   RefSeq; NP_001191067.1; NM_001204138.1.
DR   RefSeq; NP_001191068.1; NM_001204139.1. [Q9UIS9-1]
DR   RefSeq; NP_001191069.1; NM_001204140.1.
DR   RefSeq; NP_001191070.1; NM_001204141.1. [Q9UIS9-10]
DR   RefSeq; NP_001191071.1; NM_001204142.1. [Q9UIS9-6]
DR   RefSeq; NP_001191072.1; NM_001204143.1. [Q9UIS9-11]
DR   RefSeq; NP_001191080.1; NM_001204151.2. [Q9UIS9-8]
DR   RefSeq; NP_002375.1; NM_002384.2. [Q9UIS9-4]
DR   RefSeq; NP_056669.2; NM_015844.2. [Q9UIS9-7]
DR   RefSeq; NP_056670.2; NM_015845.3. [Q9UIS9-2]
DR   RefSeq; NP_056671.2; NM_015846.3. [Q9UIS9-1]
DR   RefSeq; NP_056723.2; NM_015847.3. [Q9UIS9-5]
DR   RefSeq; XP_005258328.1; XM_005258271.2. [Q9UIS9-1]
DR   RefSeq; XP_011524295.1; XM_011525993.2. [Q9UIS9-9]
DR   RefSeq; XP_011524296.1; XM_011525994.2.
DR   RefSeq; XP_011524308.1; XM_011526006.1. [Q9UIS9-11]
DR   RefSeq; XP_016881249.1; XM_017025760.1. [Q9UIS9-1]
DR   RefSeq; XP_016881259.1; XM_017025770.1. [Q9UIS9-7]
DR   RefSeq; XP_016881260.1; XM_017025771.1.
DR   RefSeq; XP_016881265.1; XM_017025776.1. [Q9UIS9-4]
DR   PDB; 1D9N; NMR; -; A=1-75.
DR   PDB; 1IG4; NMR; -; A=1-75.
DR   PDB; 4D4W; NMR; -; A=167-222.
DR   PDB; 5W9Q; X-ray; 1.80 A; A/B=330-388.
DR   PDB; 6D1T; X-ray; 2.25 A; A=1-77.
DR   PDBsum; 1D9N; -.
DR   PDBsum; 1IG4; -.
DR   PDBsum; 4D4W; -.
DR   PDBsum; 5W9Q; -.
DR   PDBsum; 6D1T; -.
DR   BMRB; Q9UIS9; -.
DR   SMR; Q9UIS9; -.
DR   BioGRID; 110322; 41.
DR   CORUM; Q9UIS9; -.
DR   IntAct; Q9UIS9; 42.
DR   MINT; Q9UIS9; -.
DR   STRING; 9606.ENSP00000468785; -.
DR   iPTMnet; Q9UIS9; -.
DR   PhosphoSitePlus; Q9UIS9; -.
DR   BioMuta; MBD1; -.
DR   DMDM; 50401200; -.
DR   EPD; Q9UIS9; -.
DR   jPOST; Q9UIS9; -.
DR   MassIVE; Q9UIS9; -.
DR   PaxDb; Q9UIS9; -.
DR   PeptideAtlas; Q9UIS9; -.
DR   PRIDE; Q9UIS9; -.
DR   ProteomicsDB; 84560; -. [Q9UIS9-1]
DR   ProteomicsDB; 84561; -. [Q9UIS9-2]
DR   ProteomicsDB; 84562; -. [Q9UIS9-4]
DR   ProteomicsDB; 84563; -. [Q9UIS9-5]
DR   ProteomicsDB; 84564; -. [Q9UIS9-6]
DR   ProteomicsDB; 84565; -. [Q9UIS9-7]
DR   ProteomicsDB; 84566; -. [Q9UIS9-8]
DR   ProteomicsDB; 84567; -. [Q9UIS9-9]
DR   Antibodypedia; 3959; 418 antibodies.
DR   CPTC; Q9UIS9; 3 antibodies.
DR   DNASU; 4152; -.
DR   Ensembl; ENST00000269468; ENSP00000269468; ENSG00000141644. [Q9UIS9-1]
DR   Ensembl; ENST00000269471; ENSP00000269471; ENSG00000141644. [Q9UIS9-2]
DR   Ensembl; ENST00000339998; ENSP00000339546; ENSG00000141644. [Q9UIS9-6]
DR   Ensembl; ENST00000347968; ENSP00000285102; ENSG00000141644. [Q9UIS9-7]
DR   Ensembl; ENST00000353909; ENSP00000269469; ENSG00000141644. [Q9UIS9-5]
DR   Ensembl; ENST00000382948; ENSP00000372407; ENSG00000141644. [Q9UIS9-1]
DR   Ensembl; ENST00000398488; ENSP00000381502; ENSG00000141644. [Q9UIS9-4]
DR   Ensembl; ENST00000398493; ENSP00000381506; ENSG00000141644. [Q9UIS9-7]
DR   Ensembl; ENST00000457839; ENSP00000405268; ENSG00000141644. [Q9UIS9-9]
DR   Ensembl; ENST00000585595; ENSP00000468430; ENSG00000141644. [Q9UIS9-9]
DR   Ensembl; ENST00000585672; ENSP00000466092; ENSG00000141644. [Q9UIS9-10]
DR   Ensembl; ENST00000587605; ENSP00000468042; ENSG00000141644. [Q9UIS9-11]
DR   Ensembl; ENST00000588937; ENSP00000467763; ENSG00000141644. [Q9UIS9-2]
DR   Ensembl; ENST00000590208; ENSP00000468785; ENSG00000141644. [Q9UIS9-12]
DR   Ensembl; ENST00000591416; ENSP00000467017; ENSG00000141644. [Q9UIS9-1]
DR   Ensembl; ENST00000591535; ENSP00000465923; ENSG00000141644. [Q9UIS9-8]
DR   GeneID; 4152; -.
DR   KEGG; hsa:4152; -.
DR   UCSC; uc002leg.4; human. [Q9UIS9-1]
DR   CTD; 4152; -.
DR   DisGeNET; 4152; -.
DR   GeneCards; MBD1; -.
DR   HGNC; HGNC:6916; MBD1.
DR   HPA; ENSG00000141644; Low tissue specificity.
DR   MIM; 156535; gene.
DR   neXtProt; NX_Q9UIS9; -.
DR   OpenTargets; ENSG00000141644; -.
DR   PharmGKB; PA30659; -.
DR   VEuPathDB; HostDB:ENSG00000141644.17; -.
DR   eggNOG; ENOG502QQE9; Eukaryota.
DR   GeneTree; ENSGT00950000183005; -.
DR   HOGENOM; CLU_031386_0_0_1; -.
DR   InParanoid; Q9UIS9; -.
DR   OMA; DCPSKAV; -.
DR   OrthoDB; 1431783at2759; -.
DR   PhylomeDB; Q9UIS9; -.
DR   PathwayCommons; Q9UIS9; -.
DR   Reactome; R-HSA-3899300; SUMOylation of transcription cofactors.
DR   SIGNOR; Q9UIS9; -.
DR   BioGRID-ORCS; 4152; 12 hits in 1018 CRISPR screens.
DR   ChiTaRS; MBD1; human.
DR   EvolutionaryTrace; Q9UIS9; -.
DR   GeneWiki; MBD1; -.
DR   GenomeRNAi; 4152; -.
DR   Pharos; Q9UIS9; Tbio.
DR   PRO; PR:Q9UIS9; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   RNAct; Q9UIS9; protein.
DR   Bgee; ENSG00000141644; Expressed in testis and 241 other tissues.
DR   ExpressionAtlas; Q9UIS9; baseline and differential.
DR   Genevisible; Q9UIS9; HS.
DR   GO; GO:0005694; C:chromosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016363; C:nuclear matrix; ISS:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; NAS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; TAS:ProtInc.
DR   GO; GO:0010385; F:double-stranded methylated DNA binding; IDA:MGI.
DR   GO; GO:0008327; F:methyl-CpG binding; IDA:UniProtKB.
DR   GO; GO:0045322; F:unmethylated CpG binding; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; TAS:ProtInc.
DR   IDEAL; IID00332; -.
DR   InterPro; IPR016177; DNA-bd_dom_sf.
DR   InterPro; IPR001739; Methyl_CpG_DNA-bd.
DR   InterPro; IPR002857; Znf_CXXC.
DR   Pfam; PF01429; MBD; 1.
DR   Pfam; PF02008; zf-CXXC; 3.
DR   SMART; SM00391; MBD; 1.
DR   SUPFAM; SSF54171; SSF54171; 1.
DR   PROSITE; PS50982; MBD; 1.
DR   PROSITE; PS51058; ZF_CXXC; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromosome; DNA-binding;
KW   Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Transcription; Transcription regulation;
KW   Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..605
FT                   /note="Methyl-CpG-binding domain protein 1"
FT                   /id="PRO_0000096258"
FT   DOMAIN          1..69
FT                   /note="MBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00338,
FT                   ECO:0000269|PubMed:10581239, ECO:0000269|PubMed:11371345,
FT                   ECO:0000269|Ref.36"
FT   ZN_FING         169..216
FT                   /note="CXXC-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00509,
FT                   ECO:0000269|PubMed:26354109"
FT   ZN_FING         217..263
FT                   /note="CXXC-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00509"
FT   ZN_FING         330..378
FT                   /note="CXXC-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00509,
FT                   ECO:0000269|PubMed:29276034"
FT   REGION          529..592
FT                   /note="Transcriptional repression domain (TRD)"
FT                   /evidence="ECO:0000269|PubMed:14555760"
FT   MOTIF           84..88
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        284..313
FT                   /note="Pro-rich"
FT   METAL           338
FT                   /note="Zinc"
FT                   /evidence="ECO:0000269|PubMed:29276034,
FT                   ECO:0007744|PDB:5W9Q"
FT   METAL           341
FT                   /note="Zinc"
FT                   /evidence="ECO:0000269|PubMed:29276034,
FT                   ECO:0007744|PDB:5W9Q"
FT   METAL           344
FT                   /note="Zinc"
FT                   /evidence="ECO:0000269|PubMed:29276034,
FT                   ECO:0007744|PDB:5W9Q"
FT   METAL           350
FT                   /note="Zinc"
FT                   /evidence="ECO:0000269|PubMed:29276034,
FT                   ECO:0007744|PDB:5W9Q"
FT   METAL           353
FT                   /note="Zinc"
FT                   /evidence="ECO:0000269|PubMed:29276034,
FT                   ECO:0007744|PDB:5W9Q"
FT   METAL           356
FT                   /note="Zinc"
FT                   /evidence="ECO:0000269|PubMed:29276034,
FT                   ECO:0007744|PDB:5W9Q"
FT   METAL           372
FT                   /note="Zinc"
FT                   /evidence="ECO:0000269|PubMed:29276034,
FT                   ECO:0007744|PDB:5W9Q"
FT   METAL           377
FT                   /note="Zinc"
FT                   /evidence="ECO:0000269|PubMed:29276034,
FT                   ECO:0007744|PDB:5W9Q"
FT   MOD_RES         297
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         391
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         399
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332"
FT   CROSSLNK        117
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        277
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        422
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        440
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        499
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        538
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        558
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         173..221
FT                   /note="Missing (in isoform 5 and isoform 10)"
FT                   /evidence="ECO:0000303|PubMed:9207790"
FT                   /id="VSP_011064"
FT   VAR_SEQ         264
FT                   /note="R -> RHLAHRLRRRHQRCQRRTPLAVAPPT (in isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042812"
FT   VAR_SEQ         304..326
FT                   /note="Missing (in isoform 2 and isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:10454587, ECO:0000303|Ref.5"
FT                   /id="VSP_011065"
FT   VAR_SEQ         326..382
FT                   /note="LQPYTNRRQNRKCGACAACLRRMDCGRCDFCCDKPKFGGSNQKRQKCRWRQC
FT                   LQFAM -> L (in isoform 11)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_054736"
FT   VAR_SEQ         327..382
FT                   /note="Missing (in isoform 4 and isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:10454587,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_011066"
FT   VAR_SEQ         327
FT                   /note="Missing (in isoform 10)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_054737"
FT   VAR_SEQ         483..528
FT                   /note="Missing (in isoform 2, isoform 4, isoform 6, isoform
FT                   8 and isoform 11)"
FT                   /evidence="ECO:0000303|PubMed:10454587, ECO:0000303|Ref.5"
FT                   /id="VSP_011068"
FT   VAR_SEQ         573..596
FT                   /note="ITEIFSLGGTRFRDTAVWLPRSKD -> EPTTQPQYSGNFDNDLYEIYLIDI
FT                   (in isoform 6)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_011069"
FT   VAR_SEQ         593..605
FT                   /note="RSKDLKKPGARKQ -> SLQGRHSGREDGCKVWETEDTVEPTSTSWNPRGWP
FT                   GTHVSLSPPPASMMWVSCRRSWCPSSQS (in isoform 2 and isoform 12)"
FT                   /evidence="ECO:0000303|PubMed:10454587"
FT                   /id="VSP_011070"
FT   VAR_SEQ         594..605
FT                   /note="SKDLKKPGARKQ -> YYHLALDWKCNCGYHLCCRSVLVP (in isoform
FT                   10)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_054738"
FT   VAR_SEQ         594..605
FT                   /note="SKDLKKPGARKQ -> AGTREGKMDVKCGRPRTQWSPRARAGTHEDGLEPMS
FT                   VSHHLQLR (in isoform 11)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_054739"
FT   VAR_SEQ         597..605
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_011071"
FT   VARIANT         401
FT                   /note="P -> A (in dbSNP:rs125555)"
FT                   /evidence="ECO:0000269|PubMed:10441743"
FT                   /id="VAR_019513"
FT   MUTAGEN         22
FT                   /note="R->A,K: Abolishes binding to methylated DNA."
FT                   /evidence="ECO:0000269|PubMed:10581239,
FT                   ECO:0000269|PubMed:11371345"
FT   MUTAGEN         30
FT                   /note="R->A: Strongly reduces binding to methylated DNA."
FT                   /evidence="ECO:0000269|PubMed:10581239,
FT                   ECO:0000269|PubMed:11371345"
FT   MUTAGEN         30
FT                   /note="R->K: No loss of binding to methylated DNA."
FT                   /evidence="ECO:0000269|PubMed:11371345"
FT   MUTAGEN         32
FT                   /note="D->A: Strongly reduces binding to methylated DNA."
FT                   /evidence="ECO:0000269|PubMed:10581239,
FT                   ECO:0000269|PubMed:11371345"
FT   MUTAGEN         34
FT                   /note="Y->A,F: Strongly reduces binding to methylated DNA."
FT                   /evidence="ECO:0000269|PubMed:10581239,
FT                   ECO:0000269|PubMed:11371345"
FT   MUTAGEN         44
FT                   /note="R->A,K: Abolishes binding to methylated DNA."
FT                   /evidence="ECO:0000269|PubMed:10581239,
FT                   ECO:0000269|PubMed:11371345"
FT   MUTAGEN         45
FT                   /note="S->A: Reduces binding to methylated DNA."
FT                   /evidence="ECO:0000269|PubMed:10581239,
FT                   ECO:0000269|PubMed:11371345"
FT   MUTAGEN         46
FT                   /note="K->A: Strongly reduces binding to methylated DNA."
FT                   /evidence="ECO:0000269|PubMed:11371345"
FT   MUTAGEN         52
FT                   /note="Y->A: No loss of binding to methylated DNA."
FT                   /evidence="ECO:0000269|PubMed:10581239,
FT                   ECO:0000269|PubMed:11371345"
FT   MUTAGEN         64
FT                   /note="F->A: Disrupts tertiary structure and abolishes DNA
FT                   binding."
FT                   /evidence="ECO:0000269|PubMed:10581239"
FT   MUTAGEN         65
FT                   /note="K->A: Strongly reduces binding to methylated DNA."
FT                   /evidence="ECO:0000269|PubMed:11371345"
FT   MUTAGEN         576
FT                   /note="I->R: Abolishes interaction with ATF7IP and
FT                   subsequent transcription repression activity."
FT                   /evidence="ECO:0000269|PubMed:15691849"
FT   CONFLICT        239
FT                   /note="H -> R (in Ref. 5; ABP02056)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        330
FT                   /note="T -> M (in Ref. 5; ABP02056)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        348..349
FT                   /note="MD -> NG (in Ref. 1; CAA71735 and 3; AAD51442/
FT                   AAD51443)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        489
FT                   /note="L -> M (in Ref. 1; CAA71735)"
FT                   /evidence="ECO:0000305"
FT   STRAND          5..7
FT                   /evidence="ECO:0007744|PDB:1IG4"
FT   TURN            9..11
FT                   /evidence="ECO:0007744|PDB:6D1T"
FT   STRAND          16..21
FT                   /evidence="ECO:0007744|PDB:6D1T"
FT   TURN            26..29
FT                   /evidence="ECO:0007744|PDB:6D1T"
FT   STRAND          31..36
FT                   /evidence="ECO:0007744|PDB:6D1T"
FT   STRAND          38..40
FT                   /evidence="ECO:0007744|PDB:1D9N"
FT   HELIX           46..53
FT                   /evidence="ECO:0007744|PDB:6D1T"
FT   STRAND          55..57
FT                   /evidence="ECO:0007744|PDB:1IG4"
FT   TURN            64..67
FT                   /evidence="ECO:0007744|PDB:6D1T"
FT   STRAND          177..179
FT                   /evidence="ECO:0007744|PDB:4D4W"
FT   HELIX           180..183
FT                   /evidence="ECO:0007744|PDB:4D4W"
FT   HELIX           194..196
FT                   /evidence="ECO:0007744|PDB:4D4W"
FT   STRAND          339..341
FT                   /evidence="ECO:0007744|PDB:5W9Q"
FT   HELIX           342..345
FT                   /evidence="ECO:0007744|PDB:5W9Q"
FT   STRAND          351..353
FT                   /evidence="ECO:0007744|PDB:5W9Q"
FT   HELIX           354..358
FT                   /evidence="ECO:0007744|PDB:5W9Q"
FT   HELIX           360..362
FT                   /evidence="ECO:0007744|PDB:5W9Q"
FT   HELIX           373..375
FT                   /evidence="ECO:0007744|PDB:5W9Q"
FT   TURN            378..380
FT                   /evidence="ECO:0007744|PDB:5W9Q"
FT   HELIX           383..385
FT                   /evidence="ECO:0007744|PDB:5W9Q"
FT   CONFLICT        Q9UIS9-7:327
FT                   /note="K -> Q (in Ref. 3; AAD51444)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   605 AA;  66607 MW;  665732782CC6A32A CRC64;
     MAEDWLDCPA LGPGWKRREV FRKSGATCGR SDTYYQSPTG DRIRSKVELT RYLGPACDLT
     LFDFKQGILC YPAPKAHPVA VASKKRKKPS RPAKTRKRQV GPQSGEVRKE APRDETKADT
     DTAPASFPAP GCCENCGISF SGDGTQRQRL KTLCKDCRAQ RIAFNREQRM FKRVGCGECA
     ACQVTEDCGA CSTCLLQLPH DVASGLFCKC ERRRCLRIVE RSRGCGVCRG CQTQEDCGHC
     PICLRPPRPG LRRQWKCVQR RCLRGKHARR KGGCDSKMAA RRRPGAQPLP PPPPSQSPEP
     TEPHPRALAP SPPAEFIYYC VDEDELQPYT NRRQNRKCGA CAACLRRMDC GRCDFCCDKP
     KFGGSNQKRQ KCRWRQCLQF AMKRLLPSVW SESEDGAGSP PPYRRRKRPS SARRHHLGPT
     LKPTLATRTA QPDHTQAPTK QEAGGGFVLP PPGTDLVFLR EGASSPVQVP GPVAASTEAL
     LQEAQCSGLS WVVALPQVKQ EKADTQDEWT PGTAVLTSPV LVPGCPSKAV DPGLPSVKQE
     PPDPEEDKEE NKDDSASKLA PEEEAGGAGT PVITEIFSLG GTRFRDTAVW LPRSKDLKKP
     GARKQ
//
